Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia

DISEASE CHARACTERISTICS: * Patients with confirmed non-M3 acute myeloid leukemia * Treated on COG-AAML03P1 or COG- AAML0531 protocols * Samples from COG-AAML0531 can come from either treatment arm, but these samples need to be independent from any patients who donated samples assayed in study COG-AAML11B2 * Patients with Down syndrome are excluded * Cryopreserved bone marrow mononuclear cell (BMMC) samples collected at diagnosis, prior to start induction therapy * Samples must have been cryopreserved at central lab within 3 days of draw at clinical site * Target of 10 X 10\^6 cells frozen * Patients' clinical annotations required after unblinding PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics